• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IRBESARTAN Drug Record

  • Summary
  • Interactions
  • Claims
  • IRBESARTAN chembl:CHEMBL1513 Approved

    Alternate Names:

    IRBESARTAN
    SR-47436
    KARVEA
    APROVEL
    SABERVEL
    IFIRMASTA
    BMS-186295
    AVAPRO
    2-BUTYL-3-{[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL}-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
    BMS 186295
    pubchem.compound:3749
    rxcui:83818
    chembl:CHEMBL1513
    chemidplus:138402-11-6
    drugbank:01029

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Year of Approval 1997
    Drug Class antihypertensive agents
    (4 More Sources)

    Publications:

    van den Meiracker et al., 1995, Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension., Hypertension
    Dol et al., 2001, Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice., J. Cardiovasc. Pharmacol.
    Adams et al., 2000, Irbesartan: review of pharmacology and comparative properties., Can J Clin Pharmacol
    Mazzolai et al., 1999, Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists., Hypertension
    Voigt et al., 2007, Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats., Eur. J. Pharmacol.
    Morsing et al., 1999, Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin., Hypertension
    Croom et al., 2004, Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy., Drugs
    Martin et al., 2004, Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan., J. Cardiovasc. Pharmacol.
    Hope et al., 1999, Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis., Am. J. Hypertens.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Waeber et al., 2003, AT1-receptor antagonism in hypertension: what has been learned with irbesartan?, Expert Rev Cardiovasc Ther
    Croom et al., 2008, Irbesartan: a review of its use in hypertension and diabetic nephropathy., Drugs
    Carraway et al., 1999, Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats., J. Cardiovasc. Pharmacol.
    Choi CI et al., 2012, CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects., Eur J Clin Pharmacol
    Hong X et al., 2005, CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population., Eur J Clin Pharmacol
    Hallberg P et al., 2002, The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial., J Hypertens
    Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens
    Kurland L et al., 2004, Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial., Am J Hypertens
    Kurland L et al., 2001, Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients., J Hypertens
    Pons et al., 2003, Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure., J. Cardiovasc. Pharmacol.
    Ortlepp JR et al., 2002, Variants of the CYP11B2 gene predict response to therapy with candesartan., Eur J Pharmacol
    Fliegner et al., 2008, Up-regulation of PPARgamma in myocardial infarction., Eur. J. Heart Fail.
    Taavitsainen et al., 2000, In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists., Eur. J. Clin. Pharmacol.
    Hallberg P et al., 2004, Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol
  • IRBESARTAN   AGTR1

    Interaction Score: 2.15

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name irbesartan,Avapro, Irbetan
    Novel drug target Established target
    Mechanism of Interaction Type-1 angiotensin II receptor antagonist

    PMIDs:
    7843749 11486244 10822210 10082498 17408613 10373224 15101793 14716205 10075381 11752352 15030294 18627212 10069682


    Sources:
    TdgClinicalTrial ChemblInteractions TEND TTD

  • IRBESARTAN   AGT

    Interaction Score: 1.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15614026 14700505 11593098


    Sources:
    PharmGKB

  • IRBESARTAN   EDN1

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15188945


    Sources:
    PharmGKB

  • IRBESARTAN   APOE

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12827021


    Sources:
    NCI

  • IRBESARTAN   APOB

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15614026


    Sources:
    PharmGKB

  • IRBESARTAN   ACE

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11593098 12065207


    Sources:
    PharmGKB

  • IRBESARTAN   SLC2A4

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18162196


    Sources:
    NCI

  • IRBESARTAN   CYP2C9

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21842338 16094537 12359989


    Sources:
    PharmGKB

  • IRBESARTAN   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10877007


    Sources:
    NCI

  • IRBESARTAN   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: IRBESARTAN

    • Version: 01-August-2011

    Alternate Names:
    IRBESARTAN Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 1997

    Publications:

  • TdgClinicalTrial: IRBESARTAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: IRBESARTAN

    • Version: 14-September-2017

    Alternate Names:
    C29130 NCI drug code

    Drug Info:

    Publications:
    Fliegner et al., 2008, Up-regulation of PPARgamma in myocardial infarction., Eur. J. Heart Fail.
    Pons et al., 2003, Effects of angiotensin II type 1 receptor blockade in ApoE-deficient mice with post-ischemic heart failure., J. Cardiovasc. Pharmacol.
    Taavitsainen et al., 2000, In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists., Eur. J. Clin. Pharmacol.

  • PharmGKB: irbesartan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Liljedahl U et al., 2004, Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment., J Hypertens
    Hallberg P et al., 2004, Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)., Clin Cardiol
    Hong X et al., 2005, CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population., Eur J Clin Pharmacol

  • DTC: IRBESARTAN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1513 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Irbesartan

    • Version: 2020.06.01

    Alternate Names:
    D00JAU TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1513

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1513

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21